Absci

Yahoo Finance • 6 days ago

The 1 AI Stock I'd Put in a Time Capsule and Open in 2036

Key Points Absci uses generative AI to design protein drugs before they are tested in a lab. Partnerships with Merck and Owkin validate Absci's hybrid AI-wet-lab drug platform. Long-term upside with this ticker depends on clinical success... Full story

Yahoo Finance • 19 days ago

Marvell Stock Climbs After AMD Reveals Surprise Stake

This article first appeared on GuruFocus. Marvell Technology (NASDAQ:MRVL) shares rose about 3% on Wednesday after Advanced Micro Devices (NASDAQ:AMD) disclosed a stake in the chipmaker in a quarterly filing, giving investors a new data p... Full story

Yahoo Finance • 21 days ago

Cathie Wood buys $12.9 million of tumbling tech stock

Cathie Wood, chief of Ark Investment Management, is known for making bold bets on fast-moving tech stocks. Sometimes her trades move just as quickly as the stocks themselves. In the week that began on May 3, Wood sold millions of dollars... Full story

Yahoo Finance • 27 days ago

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1,... Full story

Yahoo Finance • last month

Absci Corp. (ABSI) Offering Impressive Upside to Potential Investors

Absci Corp. (NASDAQ:ABSI) is one of the 10 most shorted penny stocks to buy. As of the April 23 closing, the stock carries a strongly bullish consensus sentiment. Of the 7 analysts who provided coverage, 6 assigned Buy ratings and 1 gave... Full story

Yahoo Finance • 2 months ago

Absci Q4 2025 Earnings Preview

* Absci (ABSI [https://seekingalpha.com/symbol/ABSI]) is scheduled to announce Q4 earnings results on Tuesday, March 24th, after market close. * The consensus EPS Estimate is -$0.17 [https://seekingalpha.com/symbol/ABSI/earnings/estima... Full story

Yahoo Finance • 3 months ago

Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

Absci Corporation Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s... Full story

Yahoo Finance • 3 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood is having a rough year as the co-founder, CEO and investment manager of Ark Invest. Her largest exchange-traded fund is trading 15% lower this year, a rough contrast to a winning year for many growth investors. She's not giving... Full story

Yahoo Finance • 5 months ago

Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial

Absci Corporation (NASDAQ:ABSI) is among the 12 Best Genomics Stocks to Invest In.Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial Absci Corporation (NASDAQ:ABSI) announced on December 4, 2025, that... Full story

Yahoo Finance • 6 months ago

SA Quant ranks Goldman's small-cap stocks with largest short interest

[Multi screen fintech investing gold and silver trading on digital screen corporating with AI artificial intelligence financial business data on commodity investment] primeimages Goldman Sachs analysts last week identified 50 small-cap st... Full story

Yahoo Finance • 7 months ago

Absci outlines dual ABS-201 proof-of-concept readouts by 2027 while prioritizing endometriosis expansion

Earnings Call Insights: Absci Corporation (ABSI) Q3 2025 MANAGEMENT VIEW * Sean McClain, Founder, CEO, President & Director, announced "interim Phase I results for ABS-101, acceleration of ABS-201 development in androgenetic alopecia (... Full story

Yahoo Finance • 7 months ago

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will be participating... Full story

Yahoo Finance • 8 months ago

Absci spikes as J.P. Morgan starts at Buy ahead of key catalyst

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images * Absci (NASDAQ:ABSI [https://seekingalpha.com/symbol/ABSI]) shares traded higher on Thursday after J.P. Morgan initiated its coverage on the AI-driven biotech with a... Full story

Yahoo Finance • 9 months ago

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

Absci Corporation; Oracle; AMD Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLO... Full story

Yahoo Finance • 9 months ago

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that world-renowned dermatologists Dr. Rodney... Full story

Yahoo Finance • 10 months ago

Absci Corp (NASDAQ:ABSI) Q2 2025 Earnings: Revenue Miss Sparks Market Selloff

ABSCI CORP (NASDAQ:ABSI) REPORTS Q2 2025 EARNINGS: REVENUE MISSES ESTIMATES, MARKET REACTS NEGATIVELY Absci Corp (NASDAQ:ABSI [https://www.chartmill.com/stock/quote/ABSI]) reported its second-quarter 2025 financial results, revealing a re... Full story

Yahoo Finance • 10 months ago

Absci GAAP EPS of -$0.24 misses by $0.03, revenue of $0.6M misses by $0.61M

* Absci press release [https://seekingalpha.com/pr/20198634-absci-reports-business-updates-and-second-quarter-2025-financial-and-operating-results] (NASDAQ:ABSI [https://seekingalpha.com/symbol/ABSI]): Q2 GAAP EPS of -$0.24 misses by $0.... Full story

Yahoo Finance • 10 months ago

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration w... Full story

Yahoo Finance • 10 months ago

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spa... Full story

Yahoo Finance • 10 months ago

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will re... Full story